It has been used for Ras gene mutated tumours and tumours overexpressing growth factor receptors in the Ras/Raf/Mek pathway, and inhibiting tumour angiogenesis or neovascularization via inhibition of VEGFR-2, VEGFR-3, and/or PDGFR-β including advanced clear cell renal carcinoma and hepatocellular carcinoma as well as hepatocellular carcinoma [99]. The gene discussed is RAF1; the disease is neoplasm.